x

References

  1. Feraheme® (ferumoxytol) Injection Prescribing Information.
  2. Data on file. AMAG Pharmaceuticals, Inc.
  3. Venofer® (iron sucrose injection) Prescribing Information.
  4. Ferrlecit® (sodium ferric gluconate complex in sucrose injection) Prescribing Information.
  5. INFeD® (iron dextran injection) Prescribing Information.
  6. Nulecit™ (sodium ferric gluconate complex in sucrose injection) Prescribing Information.
  7. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47(5 suppl 3):S11-S145.
  8. Nurko S. Anemia in chronic kidney disease: causes, diagnosis, treatment. Cleveland Clin J Med. 2006;73(3):289-297.
  9. Spinowitz BS, Kausz AT, Baptista J, et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol. 2008;19:1599-1605.
  10. Provenzano RS, Schiller B, Rao M, Coyne D, Brenner L, Pereira BJG. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol. 2009;4:386-393.
  11. Agarwal R, Rizkala AR, Bastani B, Kaskas MO, Leehey DJ, Besarab A. A randomized controlled trial of oral versus intravenous iron [Ferrlecit®] in chronic kidney disease. Am J Nephrol. 2006;26(5):445-454.
  12. Charytan C, Qunibi W, Bailie GR; Venofer Clinical Studies Group. Comparison of intravenous iron sucrose [Venofer®] to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract. 2005;100(3):c55-c62.
  13. Stoves J, Inglis H, Newstead CG. A randomized study of oral vs intravenous iron [Venofer®] supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant. 2001;16(5):967-974.
  14. Van Wyck DB, Roppolo M, Martinez CO, et al. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int. 2005;68(6):2846-2856.
  15. McFarlane SI, Chen S-C, Whaley-Connell AT, et al. Prevalence and associations of anemia of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis. 2008;51(suppl 2):S46-S55.
  16. Hörl WH, Macdougall IC, Rossert J, Schaefer RM. OPTA-therapy with iron and erythropoiesis-stimulating agents in chronic kidney disease. Nephrol Dial Transplant. 2007;22(suppl 3):iii2-iii6.
  17. Donne RL, Foley RN. Anaemia management and cardiomyopathy in renal failure. Nephrol Dial Transplant. 2002;17[suppl 1]:37-40.
  18. Astor BC, Muntner P, Levin A, Eustace J, Coresh J. Association of kidney function with anemia: the third national health and nutrition examination survey (1988-1994). Arch Intern Med. 2002;162:1401-1408.
  19. Kausz AT, Steinberg EP, Nissenson AR, Pereira BJG. Prevalence and management of anemia among patients with chronic kidney disease in a health maintenance organization. Dis Manage Health Outcomes. 2002;10(8):505-513.
  20. Hsu C-Y, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol. 2002;13(2):504-510.
  21. Hsu C-Y, McCulloch CE, Curhan GC. Iron status and hemoglobin level in chronic renal insufficiency. J Am Soc Nephrol. 2002;13(II):2783–2786.
  22. Gotloib L, Silverberg D, Fudin R, Shostak A. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol. 2006;19(2):161-167.
  23. Post JB, Wilkes BM, Michelis MF. Iron deficiency in patients with chronic kidney disease: potential role for intravenous iron therapy independent of erythropoietin. Int Urol Nephrol. 2006;38:719-723.
  24. Dowling TC. Prevalence, etiology, and consequences of anemia and clinical and economic benefits of anemia correction in patients with chronic kidney disease: an overview. Am J Health Syst Pharm. 2007;64(suppl 8):S3-S7.
  25. Silverberg DS, Blum M, Agbaria Z, et al. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period. Clin Nephrol. 2001;55(3):212-219.
  26. Macdougall IC, Tucker B, Thompson J, et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 1996;50(5):1694-1699.
  27. Andrews NC. Disorders of iron metabolism. N Engl J Med. 1999;341(26):1986-1995.
  28. Bron D, Meuleman N, Mascaux C. Biological basis of anemia. Semin Oncol. 2001;28(2 suppl 8):1-6.
  29. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011-1023.
  30. Eschbach JW. Iron requirements in erythropoietin therapy. Best Pract Res Clin Haematol. 2005;18:347-361.
  31. Swinkels D, Wetzels J. Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease? Nephrol Dial Transplant. 2008;23:2450-2453.
  32. Ganz, T. Hepcidin and its role in regulating systemic iron metabolism. Hematology. 2006:29-35.
  33. Fishbane S, Pollack S, Feldman H, et al. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988–2004. Clin J Am Soc Nephrol. 2009;4(1):57-61.
  34. Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol. 2006;1(suppl 1):S4-S8.
  35. Pruchnicki MC, Dasta JF. Acute renal failure in hospitalized patients: part I. Ann Pharmacother. 2002;36:1261-1267.
  36. Fishbane S. Iron management in nondialysis-dependent CKD. Am J Kidney Dis. 2007;49(6):736-743. 
  37. National Kidney Foundation. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 suppl 1):S1-266.
  38. National Kidney Foundation. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007;50(3):471-530.
  39. National Comprehensive Cancer Network®. Cancer- and chemotherapy-induced anemia. Version 1.2012. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed March 13, 2012.
  40. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant. 2004;19(1):141-149.
  41. Kalantar-Zadeh K, Kalantar-Zadeh K, Lee GH. The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease. Clin J Am Soc Nephrol. 2006;1:S9-S18.

KDOQI is a trademark of the National Kidney Foundation.
Adapted with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Cancer- and Chemotherapy-Induced Anemia V.1.2012. © 2011 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES™, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.

For the treatment of iron deficiency anemia (IDA) in adults with chronic kidney disease (CKD)

Important Safety Information for Feraheme (ferumoxytol) Injection

Indication and contraindication

Feraheme (ferumoxytol) Injection is indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease. Feraheme is contraindicated in patients with known hypersensitivity to Feraheme or any of its components.

Warnings and precautions

Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Feraheme. Observe patients for signs and symptoms of hypersensitivity during and after Feraheme administration for at least 30 minutes and until clinically stable following completion of each administration. Only administer the drug when personnel and therapies are immediately available for the treatment of anaphylaxis and other hypersensitivity reactions. Anaphylactic-type reactions, presenting with cardiac/cardiorespiratory arrest, clinically significant hypotension, syncope, and unresponsiveness have been reported in the post-marketing experience. In clinical studies, serious hypersensitivity reactions were reported in 0.2% (3/1,726) of subjects receiving Feraheme. Other adverse reactions potentially associated with hypersensitivity (e.g., pruritus, rash, urticaria or wheezing) were reported in 3.7% (63/1,726) of subjects. Severe adverse reactions of clinically significant hypotension have been reported in the post-marketing experience. In clinical studies, hypotension was reported in 1.9% (33/1,726) of subjects, including three patients with serious hypotensive reactions. Monitor for signs and symptoms of hypotension following each Feraheme injection. Excessive therapy with parenteral iron can lead to excess storage of iron with the possibility of iatrogenic hemosiderosis. Patients should be regularly monitored for hematologic response during parenteral iron therapy, noting that lab assays may overestimate serum iron and transferrin bound iron values in the 24 hours following administration of Feraheme. As a superparamagnetic iron oxide, Feraheme may transiently affect magnetic resonance diagnostic imaging studies for up to 3 months following the last Feraheme dose. Feraheme will not affect X-ray, CT, PET, SPECT, ultrasound, or nuclear imaging.

Adverse reactions

In clinical trials, the most commonly occurring adverse reactions in Feraheme treated patients versus oral iron treated patients reported in ≥ 2% of chronic kidney disease patients were diarrhea (4.0% vs. 8.2%), nausea (3.1% vs. 7.5%), dizziness (2.6% vs. 1.8%), hypotension (2.5% vs. 0.4%), constipation (2.1% vs. 5.7%) and peripheral edema (2.0% vs. 3.2%). In clinical trials, adverse reactions leading to treatment discontinuation and occurring in 2 or more Feraheme treated patients included hypotension, infusion site swelling, increased serum ferritin level, chest pain, diarrhea, dizziness, ecchymosis, pruritus, chronic renal failure, and urticaria.

Post-marketing safety experience

The following adverse reactions have been identified during post-approval use of Feraheme. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

The following serious adverse reactions have been reported from the post-marketing spontaneous reports with Feraheme: life-threatening anaphylactic-type reactions, cardiac/cardiorespiratory arrest, clinically significant hypotension, syncope, unresponsiveness, loss of consciousness, tachycardia/rhythm abnormalities, angioedema, ischemic myocardial events, congestive heart failure, pulse absent, and cyanosis. These adverse reactions have occurred up to 30 minutes after the administration of Feraheme injection. Reactions have occurred following the first dose or subsequent doses of Feraheme.